Del Bianco, P.; Stagni, C.; Giunco, S.; Fabozzi, A.; Elefanti, L.; Pellegrini, S.; Vecchiato, A.; Pigozzo, J.; Zamuner, C.; De Rossi, A.;
et al. TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients. Cancers 2020, 12, 946.
https://doi.org/10.3390/cancers12040946
AMA Style
Del Bianco P, Stagni C, Giunco S, Fabozzi A, Elefanti L, Pellegrini S, Vecchiato A, Pigozzo J, Zamuner C, De Rossi A,
et al. TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients. Cancers. 2020; 12(4):946.
https://doi.org/10.3390/cancers12040946
Chicago/Turabian Style
Del Bianco, Paola, Camilla Stagni, Silvia Giunco, Alessio Fabozzi, Lisa Elefanti, Stefania Pellegrini, Antonella Vecchiato, Jacopo Pigozzo, Carolina Zamuner, Anita De Rossi,
and et al. 2020. "TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients" Cancers 12, no. 4: 946.
https://doi.org/10.3390/cancers12040946
APA Style
Del Bianco, P., Stagni, C., Giunco, S., Fabozzi, A., Elefanti, L., Pellegrini, S., Vecchiato, A., Pigozzo, J., Zamuner, C., De Rossi, A., De Nicolo, A., & Menin, C.
(2020). TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients. Cancers, 12(4), 946.
https://doi.org/10.3390/cancers12040946